Debate: Should JAK Inhibitors use be Limited to Hydroxyurea-resistant/intolerant PV Patients?

The "JAK Inhibitors for the Successful Management of Patients with Polycythemia Vera” symposium was recorded at the 2015 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes Congress held in Alexandria, VA, August 28-29, 2015. This symposium highlights key clinical data and recommendations related to the diagnosis, prognosis and therapy of patients with polycythemia vera and the integration of JAK inhibitors into clinical practice.

In this presentation, Dr. Srdan Verstovsek argues that JAK inhibitors should not be limited to hydroxyurea-resistant or intolerant patients.

Earn accreditation for an activity that is supplementary to this webcast at the following location:
http://elc.imedex.com/Shared/S....ervices/ActivityRedi

© 2015 Imedex, LLC.

Please note that if you are under 18, you won't be able to access this site.

Up next

Debate: Should JAK Inhibitors use be Limited to Hydroxyurea-resistant/intolerant PV Patients? - No

Up next

Language